Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis (CLLS) reported its monthly share capital and voting rights as of 02/28/2026. The company shows a total of 100,590,994 shares and 105,825,561 total voting rights on Euronext Growth (ISIN FR0010425595).

Contact details for media and investor relations are provided for further information.

Key Figures

Total shares: 100,590,994 Total voting rights: 105,825,561

2 metrics

Total shares 100,590,994 Total number of shares in the capital as of 02/28/2026

Total voting rights 105,825,561 Total number of voting rights as of 02/28/2026

Market Reality Check

Price: $3.75 Vol: Volume 23,809 is below th...

low vol

$3.75 Last Close

Volume Volume 23,809 is below the 20-day average of 40,002 (relative volume 0.6x). low

Technical Price $3.75 is trading above the 200-day MA at $3.22.

Peers on Argus

CLLS fell 3.68% while momentum peers like ABEO and TECX appeared in scanners mov...

2 Up

CLLS fell 3.68% while momentum peers like ABEO and TECX appeared in scanners moving up, suggesting stock-specific trading rather than a sector-wide move.

Historical Context

5 past events · Latest: Feb 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 04	Monthly capital update	Neutral	-1.1%	Standard monthly disclosure of total shares and voting rights as of Jan 31.
Jan 08	Strategy & pipeline	Positive	-1.6%	Outlined 2026 strategy, CAR-T milestones, and cash runway into H2 2027.
Jan 05	Monthly capital update	Neutral	-3.1%	Monthly report of total shares and voting rights as of Dec 31, 2025.
Dec 15	Arbitral decision	Neutral	-15.2%	Arbitral ruling with partial license termination for UCART19 V1 and other claims dismissed.
Dec 08	Clinical data update	Positive	-2.5%	Presented strong Phase 1 eti-cel efficacy data in r/r NHL at ASH 2025.

Pattern Detected

News, including positive clinical and strategic updates, has often been followed by negative price reactions, indicating a pattern of selling into news.

Recent Company History

Over the past few months, Cellectis has mixed routine disclosures with strategic and clinical updates. Monthly share capital and voting-rights reports on 12/31/2025 and 01/31/2026 showed stable share counts and modest negative moves. A 2026 strategy update with multiple CAR-T catalysts on 01/08/2026 and positive eti-cel data at ASH 2025 on 12/08/2025 were both followed by price declines. An arbitral decision on 12/15/2025 also coincided with a sharp drop, underscoring a tendency for weakness around news.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-07-02

The company has an effective Form F-3 shelf registration dated 2025-07-02, expiring on 2028-07-02, with 0 recorded usages to date. Specific capacity amounts were not provided.

Market Pulse Summary

This announcement reports monthly share capital and voting rights, listing 100,590,994 shares and 10...

Analysis

This announcement reports monthly share capital and voting rights, listing 100,590,994 shares and 105,825,561 voting rights as of 02/28/2026. It follows a series of news items where both clinical and strategic updates often coincided with price pressure. The company also has an effective Form F-3 shelf registration dated 2025-07-02, with no recorded usage. Investors tracking this name may watch for future clinical milestones and any utilization of its registration capacity.

Key Terms

isin

1 terms

isin financial

"Listing market: Euronext Growth ISIN code: FR0010425595"

A 12-character International Securities Identification Number (ISIN) is a unique code that acts like a passport for a specific stock, bond or other tradable security so it can be identified worldwide. Investors and systems use it to ensure they are buying, selling and tracking the exact same instrument across exchanges and data feeds, which prevents costly mix-ups and makes portfolio reporting, settlement and regulatory checks simpler and more reliable.

AI-generated analysis. Not financial advice.

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, March 04, 2026 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
02/28/2026	100,590,994	105,825,561

For further information on Cellectis, please contact:         

Media contacts:              
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com  
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93      
    
Investor Relations contact:           
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com   

Attachment

• Voting_Rights_PR_February_2026_EN

FAQ

How many shares did Cellectis (CLLS) report on 02/28/2026?

Cellectis reported 100,590,994 total shares as of 02/28/2026. According to Cellectis, this figure represents the total number of shares in capital recorded on the Euronext Growth register at that date.

What were the total voting rights for Cellectis (CLLS) on 02/28/2026?

The company reported 105,825,561 total voting rights on 02/28/2026. According to Cellectis, this number reflects all voting rights attached to outstanding shares, including any double voting rights where applicable.

Where is Cellectis (CLLS) listed and what is its ISIN code?

Cellectis is listed on Euronext Growth with ISIN FR0010425595. According to Cellectis, the listing market and ISIN identify the company's securities for trading and regulatory reporting.

Who can investors contact at Cellectis (CLLS) for questions about share capital?

Investors can contact Arthur Stril, CFO & CBO, via the investors@cellectis.com address. According to Cellectis, investor relations queries should be directed to that contact for capital and voting-rights information.

Does the February 2026 voting rights update for Cellectis (CLLS) indicate a corporate action?

No immediate corporate action is indicated by the voting-rights update; it reports current counts. According to Cellectis, this is a routine monthly disclosure under applicable market regulations rather than an announcement of a transaction.